Antibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF-228-NA - Provider product page
- Provider
- R&D Systems
- Product name
- Human gp130 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human gp130 in direct ELISAs and Western blots. In direct ELISAs, less than 2% cross-reactivity with recombinant rat gp130, recombinant mouse gp130, recombinant human (rh) IL-1 sRI, rhIL-1 sRII, rhIL-2 sR beta , rhIL-2 sR gamma , rhIL-4 sR, and rhIL-6 sR is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
P40189
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Disturbances in the LIF pathway in the endometrium among women with unexplained infertility.
Expression of leukemia inhibitory factor and its receptors is increased during differentiation of human embryonic stem cells.
Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.
The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling.
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
McFarland BC, Hong SW, Rajbhandari R, Twitty GB Jr, Gray GK, Yu H, Benveniste EN, Nozell SE
PloS one 2013;8(11):e78728
PloS one 2013;8(11):e78728
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG
Nature genetics 2012 Jul 1;44(8):852-60
Nature genetics 2012 Jul 1;44(8):852-60
Disturbances in the LIF pathway in the endometrium among women with unexplained infertility.
Aghajanova L, Altmäe S, Bjuresten K, Hovatta O, Landgren BM, Stavreus-Evers A
Fertility and sterility 2009 Jun;91(6):2602-10
Fertility and sterility 2009 Jun;91(6):2602-10
Expression of leukemia inhibitory factor and its receptors is increased during differentiation of human embryonic stem cells.
Aghajanova L, Skottman H, Strömberg AM, Inzunza J, Lahesmaa R, Hovatta O
Fertility and sterility 2006 Oct;86(4 Suppl):1193-209
Fertility and sterility 2006 Oct;86(4 Suppl):1193-209
Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.
Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL
Cancer research 2005 Oct 1;65(19):8896-904
Cancer research 2005 Oct 1;65(19):8896-904
The N-terminal cytokine binding domain of LIFR is required for CNTF binding and signaling.
He W, Gong K, Smith DK, Ip NY
FEBS letters 2005 Aug 15;579(20):4317-23
FEBS letters 2005 Aug 15;579(20):4317-23
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H
Circulation 2003 Feb 18;107(6):798-802
Circulation 2003 Feb 18;107(6):798-802
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H
Circulation 2003 Feb 18;107(6):798-802
Circulation 2003 Feb 18;107(6):798-802
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Proliferation Induced by Oncostatin M/OSM and Neutralization by Human gp130 Antibody. Recombinant Human Oncostatin M/OSM (Catalog # 295-OM) stimulates proliferation in the TF-1 human erythroleukemic cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human Oncostatin M/OSM (0.8 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human gp130 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF-228-NA). The ND50 is typically 2-10 µg/mL.